Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML

Clinical trial NCT06611839 · RECRUITING

Trial details

NCT number: NCT06611839
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

AML IDH1 Mutation Treatment

Start date: 2025-10-17
Primary completion: 2026-10-01
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.